US approval gives Pfizer the first and second-line settings.
ApexOnco Front Page
Recent articles
But, like Merck two weeks ago, GSK has failed to hit overall survival.
The French group takes a shot at Perspective with its second bet on Orano Med.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
The Hutchmed-originated savolitinib moves towards its first US approval.
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
